XML 98 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Geographic and Product Data
6 Months Ended
Jun. 28, 2013
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
Note 9 — Geographic and Product Data
 
The Company markets and sells its products in over 60 countries and has manufacturing sites in the United States, Switzerland and Japan. Other than the United States, Japan, Korea, China, and Spain the Company does not conduct business in any country in which its sales exceed 5% of consolidated sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers is set forth below (in thousands):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
June 28,
2013
 
June 29,
2012
 
June 28,
2013
 
June 29,
2012
 
United States
 
$
3,154
 
$
3,216
 
$
6,394
 
$
6,390
 
Japan
 
 
4,648
 
 
4,094
 
 
9,387
 
 
7,951
 
China
 
 
2,230
 
 
2,141
 
 
4,301
 
 
4,247
 
Korea
 
 
1,834
 
 
1,721
 
 
3,869
 
 
3,624
 
Spain
 
 
1,163
 
 
531
 
 
2,454
 
 
1,041
 
Other
 
 
5,135
 
 
4,239
 
 
9,760
 
 
8,198
 
Total
 
$
18,164
 
$
15,942
 
$
36,165
 
$
31,451
 
 
100% of the Company’s sales are generated from the ophthalmic surgical product segment and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line is as follows (in thousands):
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
June 28,
2013
 
June 29,
2012
 
June 28,
2013
 
June 29,
2012
 
ICLs
 
$
11,261
 
$
8,606
 
$
21,892
 
$
17,211
 
IOLs
 
 
5,863
 
 
6,774
 
 
12,211
 
 
13,132
 
Core products
 
 
17,124
 
 
15,380
 
 
34,103
 
 
30,343
 
Other Surgical Products
 
 
1,040
 
 
562
 
 
2,062
 
 
1,108
 
Total
 
$
18,164
 
$
15,942
 
$
36,165
 
$
31,451
 
 
The Company sells its products internationally, which subjects the Company to several potential risks, regional/country economic conditions and regulatory requirements, including fluctuating foreign currency exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, United States and foreign export and import duties and tariffs, and political instability.